Literature DB >> 22102307

CCR5 promoter haplotype transcription complex characterization.

Daifeng Jiang1, Srinivas Mummidi, Sunil K Ahuja, Harry W Jarrett.   

Abstract

CC chemokine receptor 5 (CCR5) is a major coreceptor for cell entry of human immunodeficiency virus (HIV); its expression is highly associated with virus replication and susceptibility. Single nucleotide polymorphisms (SNPs) in the CCR5 promoter play a critical role in CCR5 transcriptional regulation. HHA and HHE represent two contrasting haplotypes of CCR5 with only two base pair differences in the promoter. Identifying the transcription factors (TFs) that differentially bind to the polymorphic sites (the SNPs) in CCR5 haplotypes aids understanding HIV transmission/pathogenesis. Promoter trapping and two-dimensional southwestern blot analysis, to purify transcription complex and identify the differential TFs binding profile, is combined with HPLC-ESI-MS/MS, to determine those proteins specifically bound to one haplotype. This strategy reveals clear differences in haplotype-TF binding and has great promise for investigating how the CCR5 haplotypes may affect HIV-AIDS (acquired immune deficiency syndrome) susceptibility or disease progression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102307      PMCID: PMC3326658          DOI: 10.1353/hpu.2011.0169

Source DB:  PubMed          Journal:  J Health Care Poor Underserved        ISSN: 1049-2089


  24 in total

1.  Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.

Authors:  E Gonzalez; R Dhanda; M Bamshad; S Mummidi; R Geevarghese; G Catano; S A Anderson; E A Walter; K T Stephan; M F Hammer; A Mangano; L Sen; R A Clark; S S Ahuja; M J Dolan; S K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Authors:  Janelle R Salkowitz; Shannon E Bruse; Howard Meyerson; Hernan Valdez; Donald E Mosier; Clifford V Harding; Peter A Zimmerman; Michael M Lederman
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

3.  Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

Authors:  R Liu; W A Paxton; S Choe; D Ceradini; S R Martin; R Horuk; M E MacDonald; H Stuhlmann; R A Koup; N R Landau
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

4.  Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.

Authors:  S Mummidi; M Bamshad; S S Ahuja; E Gonzalez; P M Feuillet; K Begum; M C Galvis; V Kostecki; A J Valente; K K Murthy; L Haro; M J Dolan; J S Allan; S K Ahuja
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

5.  Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1.

Authors:  S E Kuhmann; E J Platt; S L Kozak; D Kabat
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

7.  Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression.

Authors:  Di Feng; Niquiche Sangster-Guity; Rivka Stone; Justyna Korczeniewska; Margo E Mancl; Patricia Fitzgerald-Bocarsly; Betsy J Barnes
Journal:  J Immunol       Date:  2010-10-08       Impact factor: 5.422

8.  Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.

Authors:  A Mangano; E Gonzalez; R Dhanda; G Catano; M Bamshad; A Bock; R Duggirala; K Williams; S Mummidi; R A Clark; S S Ahuja; M J Dolan; R Bologna; L Sen; S K Ahuja
Journal:  J Infect Dis       Date:  2001-05-02       Impact factor: 5.226

9.  Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients.

Authors:  E Stylianou; A Yndestad; L I Sikkeland; V Bjerkeli; J K Damås; T Haug; H G Eiken; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

10.  R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms.

Authors:  Tatsuyoshi Kawamura; Forrest O Gulden; Makoto Sugaya; David T McNamara; Debra L Borris; Michael M Lederman; Jan M Orenstein; Peter A Zimmerman; Andrew Blauvelt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  3 in total

1.  Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans.

Authors:  Gemma W Koor; Maria Paximadis; Anabela C P Picton; Fidan Karatas; Shayne A Loubser; Weijing He; Sunil K Ahuja; Richard E Chaisson; Neil Martinson; Osman Ebrahim; Caroline T Tiemessen
Journal:  Clin Immunol       Date:  2019-05-15       Impact factor: 3.969

Review 2.  Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Authors:  Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

Review 3.  Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important?

Authors:  Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2020-08-26       Impact factor: 3.342

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.